Novartis
CompanyUnited States
Novartis develops 8 assets, the furthest approved (everolimus in advanced breast cancer). Mostly small molecule and vaccine acting on lipid and ceramide metabolism, inflammation and autophagy; based in the United States.
- Assets
- 8
- Furthest
- Approved
- Grants
- 3
- Trials
- 392
- Signals
- 2
Pipeline
8Selective inhibitor of mTOR complex 1 (mTORC1)
ApprovedSmall moleculeAutophagymTOR signallingadvanced breast cancerAngiomyolipoma
HMG-CoA reductase inhibitor and PPAR-alpha agonist combination regulating lipid metabolism.
ApprovedSmall moleculeLipid and ceramide metabolismPPARAcerebrovascular diseasecoronary heart disease
Dipeptidyl peptidase-4 (DPP-4) inhibitor preventing degradation of incretin hormones
ApprovedSmall moleculeAMPK signallingInsulin/IGF-1 signallingdiabetestype 2 diabetes
5 more assets
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms10
- Trials695
- Signals10
- Integrity notices10
- Similar companies6
Updated 7 Oct 2026 · 536 sources